Dow Up0.59% Nasdaq Up0.75%

More On ALPMF

Quotes

Charts

News & Info

Company

Analyst Coverage

Ownership

  • Major Holders
  • Insider Transactions
  • Insider Roster

Financials

  • Income Statement
  • Balance Sheet
  • Cash Flow

Astellas Pharma, Inc. (ALPMF)

-Other OTC
14.65 Sep 12, 12:32PM EDT
|Pre-Market : NaN
ProfileGet Profile for:
Astellas Pharma, Inc.
2-3-11 Nihonbashi-Honcho
Chuo-ku
Tokyo, 103-8411
Japan - Map
Phone: 81 3 3244 3000
Website: http://www.astellas.com

Details 
Index Membership:N/A
Sector:N/A
Industry:N/A
Full Time Employees:17,649

Business Summary 

Astellas Pharma Inc. manufactures, markets, and imports/exports pharmaceutical products worldwide. The company focuses on therapeutic areas of urology, immunology and infectious diseases, oncology, neuroscience, and diabetes mellitus complications and kidney diseases. Its products include Prograf, an immunosuppressant to prevent rejection in organ transplants; Protopic for the treatment of atopic dermatitis in the topical immunomodulator class; Vesicare, a treatment for overactive bladder; Harnal, an a1 blocking agent for the treatment of benign prostatic hyperplasia; and Funguard, a candin antifungal agent. The company’s products also comprise Geninax, an oral quinolone antibacterial agent; Celecox, a selective COX-2 inhibitor; Lipitor, a treatment for hypercholesterolemia; Micardis, a treatment hypertension; Gaster, a treatment for peptic ulcers and gastritis; Myslee, a hypnotic; Cefzon, an oral cephalosporin; Seroquel, an antipsychotic agent; Dorner, a treatment for chronic arterial occlusion; Nasea, an antagonist; Regnite, a treatment for restless legs syndrome; and Kiklin, a treatment for hyperphatemia. In addition, it offers Lexiscan and Adenoscan, which are pharmacologic stress agents; Tarceva, a treatment for non-small cell lung cancer; Vaprisol, a treatment for euvolemic hyponatremia; AmBisome, a systemic antifungal agent; Eligard, a treatment for advanced prostate cancer; Locoid, a topical corticosteroid; Zineryt, a treatment for acne; Locobase, a treatment for dry skin; and Dificlir, a novel treatment for CDI. It has a strategic alliance with Amgen Inc.; a collaborative research agreement with Immuno-Biological Laboratories Co., Ltd.; a compound library sharing partnership with Daiichi Sankyo Company, Limited; and a strategic partnership with ClearPath Development Company. The company was founded in 1923 and is headquartered in Tokyo, Japan.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Astellas Pharma, Inc.

Key Executives 
 PayExercised
Mr. Yoshihiko Hatanaka ,
Chief Exec. Officer, Pres and Representative Director
N/AN/A
Mr. Yasumasa Masuda ,
Sr. Corp. Exec., Chief Financial Officer and Sr. VP
N/AN/A
Mr. Mitsunori Matsuda ,
Corp. Exec., Pres of Technology and Sr. VP
N/AN/A
Mr. Yoshiro Miyokawa ,
Chief Admin. Officer, Chief Compliance Officer, executive VP, Representative Director, Chairman of Compensation Committee and Chairman of Global Compliance Committee
N/AN/A
Mr. Jeffrey A. Winton , 56
Chief Communications Officer and Sr. VP
N/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.